The results of our double-blind, placebo-controlled, randomized Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVEN-TAS) trial show no benefit of repetitive intra-arterial infusion of autologous bone marrow-derived mononuclear cells over placebo on prespecified clinical outcomes (eg, major amputation, quality of life, wound healing) in patients with severe, nonrevascularizable peripheral artery disease. The lack of benefit of autologous bone marrow-derived mononuclear cells in our study does not exclude the potential benefit of alternative cell sources or subpopulations, different administration locations and routes, or that in patients with milder disease. Further study is warranted to investigate whether cell therapy strategies with selected cell populations, enhanced bone marrow cell function, or different modes of administration can provide therapeutic benefit in patients with advanced peripheral artery disease. The general improvement in clinical outcomes observed in both the placebo-and bone marrow-derived mononuclear celltreated groups during follow-up stresses the need for future randomized clinical trials to implement a rigorous doubleblinded, placebo-controlled design. See p 851.
Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries
This article systematically summarizes the published literature concerning patients with myocardial infarction with nonobstructive coronary arteries. These patients account for 6% of all those experiencing an acute myocardial infarct. Although they have a similar prevalence for many risk factors to those with myocardial infarction associated with obstructive coronary artery disease, in comparison they tend to be younger, more often female, and less likely to have hyperlipidemia. Moreover, although their prognosis is better than those with obstructive coronary artery disease, it remains guarded with an all-cause mortality of 4.7% (95% confidence interval, 2.6%-6.9%) at 12 months. The key clinical practice implication from this study is that myocardial infarction with nonobstructive coronary arteries should be considered as a working diagnosis that necessitates further investigation for an underlying cause (ie, similar to that required for a heart failure diagnosis). Important causes include myocarditis, Tako-tsubo cardiomyopathy, vasospastic angina, and hereditary thrombophilia disorders, all of which require different management strategies. Cardiac magnetic resonance imaging is a useful initial investigation to delineate some of these causes. Assessment for coronary artery spasm and thrombophilia disorders should also be considered. The importance of identifying these causes resides with the potential to use effective therapies that otherwise may not have been considered and that may impact on prognosis (eg, calcium channel blockers for coronary spasm). Accordingly, there is the potential to reduce the guarded prognosis in these patients. See p 861.
Rapid and Body Weight-Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass: Role of Glucagon-Like Peptide-1
Obesity is a public health priority because of the associated increase in morbidity and cardiovascular mortality. Currently, the most effective treatment for severe obesity is bariatric surgery, which induces sustained weight loss and is associated with a long-term reduction in obesity-associated comorbidity and cardiovascular mortality. The current understanding of the mechanisms underlying these beneficial effects suggests that a crucial role is played by the unique metabolic and hormonal changes after bariatric surgeries, in particular Roux-en-Y gastric bypass or vertical sleeve gastrectomy, rather than simply as the consequence of weight loss. The gut hormone glucagon-like peptide-1 (GLP-1), which increases rapidly after certain bariatric surgeries such as Roux en-Y gastric bypass and sleeve gastrectomy, but not after dietary restriction, seems to specifically mediate some metabolic benefits of bariatric surgery. In the present study, which uses a rat model of Roux-en-Y gastric bypass, higher plasma levels of GLP-1 were associated with increased aortic nitric oxide bioavailability, improved endothelium-dependent relaxation, and normalized endothelium-protective properties of high-density lipoprotein independently of weight loss. Furthermore, in morbidly obese patients, increased plasma levels of GLP-1 after Roux-en-Y gastric bypass were associated with a rapid improvement in the endothelium-protective properties of high-density lipoprotein, confirming the clinical relevance of the experimental animal findings. Thus, Roux-en-Y gastric bypass exerts rapid endotheliumprotective effects beyond the surgery-induced weight loss. These effects are mediated, at least in part, by GLP-1 and GLP-1 receptor signaling. These findings may allow the identification of novel and less invasive treatment strategies targeting molecular cardiovascular and metabolic pathways affected by obesity. See p 871.
Racial Disparities in Outcomes of Adult Heart Transplantation
In this analysis of >18 000 heart transplant patients over a 10-year period in the United States, we demonstrate that black recipients are at increased risk of posttransplant mortality, a finding that applies to both poor-performing and excellentperforming transplant centers. A higher proportion of blacks were transplanted at centers with higher-than-expected Volume 131 ◼ Number 10 ◼ March 10, 2015
